China Vaccine Cold Chain Intelligence Whitepaper 2026

Executive summary

This whitepaper (in drafting, planned release Q2 2026) reviews the current state, bottlenecks and discussable future pathways of vaccine cold chain intelligence in China. Data sources include anonymized records of verified Mingyuan projects in the institute case library, public-source syntheses of eight global systems, and internal research-team workshops. The paper will propose a triadic technical discussion framework ("digital twin + AI inspection + federated emergency"). All forecasts carry explicit verification criteria, open for reader audit by 2030.

Key findings

1. 01China’s vaccine cold chain is approaching the transition between mechanical and smart cold chain, propelled by multiple converging forces
2. 02Per-warehouse digital twin cost is on a declining trajectory; exact annual target ranges will be updated each year in the whitepaper
3. 03Smart replenishment shows structural improvement space over rule-based systems when combining structured and unstructured signals (exact figures per partner disclosures)
4. 04Provincial-level federated dispatch is a direction referenced in policy documents; no fully-built instance exists yet
5. 05The Chinese vendor opportunity for global markets lies within the WHO PQS / Gavi CCEOP pathway, which is reusable

On this page

1. 01导言：疫苗冷链的技术转折区间
2. 02现状扫描：明远案例库样本的共性观察
3. 03技术讨论框架：数字孪生 + AI 巡检 + 联邦应急
4. 04国际对标：与 WHO / Gavi / UNICEF / CDC USA / EU 体系对照（公开资料整理）
5. 05研究团队内部工作坊：若干方向性判断
6. 06可审计的长周期预测（含判定标准）
7. 07风险、局限与未解决问题
8. 08研究方法、数据来源与引用规范